Please Wait.....

Report

NA Bladder Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report I 2023-04-01 I 155 Pages I Data Bridge Market Research

The North America bladder cancer diagnostics market is projected to register a substantial CAGR of 9.1% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
North America Bladder Cancer Diagnostics Market, By Test Type (Cystoscopy, Urine Lab Test, Biopsy, Imaging Test, and Others), Stages (Stage I, Stage II, Stage III, and Stage IV), Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, and Other Cancer Types), End User (Hospital, Diagnostic Imaging Centers, Cancer Research Institutes, Independent Diagnostic Laboratories, and Associated Labs), Distribution Channel (Direct Tender and Retail Sales), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the North America bladder cancer diagnostics market are:
- Rising incidence of bladder cancer globally
- Rising awareness for the early diagnosis of bladder cancer

Market Players:
Some of the key market players in the North America bladder cancer diagnostics market are listed below:

- F. Hoffmann-La Roche Ltd
- Merck KGaA
- Thermo Fisher Scientific Inc.
- Koninklijke Philips N.V.
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- FUJIFILM Corporation
- CANON MEDICAL SYSTEMS CORPORATION
- Siemens Healthcare GmbH
- BD
- Illumina
- Neusoft Corporation
- Abbott
- General Electric Company
- Hologic
- QIAGEN
- Cepheid.
- Ambu A/S
- Time Medical Holding.
- MinFound Medical Systems Co., Ltd.

TABLE OF CONTENTS
1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF THE NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET 26
1.4 CURRENCY AND PRICING 27
1.5 LIMITATIONS 28
1.6 MARKETS COVERED 28
2 MARKET SEGMENTATION 30
2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 DBMR TRIPOD DATA VALIDATION MODEL 33
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.6 MULTIVARIATE MODELLING 37
2.7 TEST TYPE SEGMENT LIFELINE CURVE 37
2.8 MARKET END USER COVERAGE GRID 38
2.9 DBMR MARKET POSITION GRID 39
2.10 VENDOR SHARE ANALYSIS 40
2.11 SECONDARY SOURCES 41
2.12 ASSUMPTIONS 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHTS 44
4.1 PESTLE ANALYSIS 45
4.2 PORTER'S FIVE FORCES MODEL 46
5 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHT 47
6 REGULATORY FRAMEWORK 49
6.1 REGULATORY SCENARIO IN THE U.S 49
7 MARKET OVERVIEW 50
7.1 DRIVERS 52
7.1.1 RISING INCIDENCE OF BLADDER CANCER NORTH AMERICALY 52
7.1.2 RISING AWARENESS FOR THE EARLY DIAGNOSIS OF BLADDER CANCER 52
7.1.3 IMPROVED IMAGING TECHNIQUES AND TECHNOLOGY 53
7.1.4 INNOVATIONS IN DRUG DELIVERY TO BLADDER CANCER CELLS 53
7.2 RESTRAINTS 54
7.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS AND TREATMENT OF BLADDER CANCER 54
7.2.2 SIDE EFFECTS OF BLADDER CANCER TREATMENT DRUGS & THERAPIES 54
7.2.3 LATE DIAGNOSIS OF BLADDER CANCER RESULTING IN POOR PROGNOSIS 54
7.3 OPPORTUNITIES 55
7.3.1 INCREASE IN DIAGNOSTIC PROCEDURES FOR BLADDER CANCER 55
7.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS 55
7.3.3 INCREASE IN THE GERIATRIC POPULATION 56
7.4 CHALLENGES 56
7.4.1 ETHICAL CHALLENGES FACED DURING BLADDER CANCER TESTING 56
7.4.2 STRINGENT REGULATIONS AMONG BLADDER CANCER DIAGNOSTICS TESTS AND PROCEDURES 57
8 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 58
8.1 OVERVIEW 59
8.2 CYSTOSCOPY 62
8.3 URINE LAB TEST 62
8.3.1 URINE CYTOLOGY 64
8.3.2 URINALYSIS 64
8.3.3 URINE TUMOR MARKER TEST 64
8.3.4 URINE CULTURE 64
8.3.5 OTHERS 64
8.4 BIOPSY 64
8.5 IMAGING TEST 65
8.5.1 MAGNETIC RESONANCE IMAGING (MRI) SCAN 66
8.5.2 COMPUTED TOMOGRAPHY (CT) SCAN 66
8.5.3 ULTRASOUND 66
8.5.4 INTRAVENOUS PYELOGRAM (IVP) 67
8.6 OTHERS 67
9 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY STAGES 68
9.1 OVERVIEW 69
9.2 STAGE IV 72
9.3 STAGE III 72
9.4 STAGE II 73
9.5 STAGE I 74
10 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 76
10.1 OVERVIEW 77
10.2 TRANSITIONAL CELL BLADDER CANCER 80
10.3 SQUAMOUS CELL BLADDER CANCER 81
10.4 OTHER CANCER TYPES 82
11 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY END USER 83
11.1 OVERVIEW 84
11.2 HOSPITAL 87
11.3 DIAGNOSTIC IMAGING CENTERS 87
11.4 CANCER RESEARCH INSTITUTES 88
11.5 INDEPENDENT DIAGNOSTIC LABORATORIES 89
11.6 ASSOCIATED LABS 90
12 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 91
12.1 OVERVIEW 92
12.2 DIRECT TENDER 95
12.3 RETAIL SALES 95
13 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, BY REGION 97
13.1 NORTH AMERICA 98
13.1.1 U.S. 105
13.1.2 CANADA 107
13.1.3 MEXICO 109
14 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 111
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 111
15 SWOT ANALYSIS 112
16 NORTH AMERICA BLADDER CANCER DIAGNOSTICS MARKET 113
16.1 F. HOFFMANN- LA ROCHE LTD 113
16.1.1 COMPANY SNAPSHOT 113
16.1.2 REVENUE ANALYSIS 113
16.1.3 COMPANY SHARE ANALYSIS 114
16.1.4 PRODUCT PORTFOLIO 114
16.1.5 RECENT DEVELOPMENTS 114
16.2 MERCK KGAA 115
16.2.1 COMPANY SNAPSHOT 115
16.2.2 REVENUE ANALYSIS 115
16.2.3 COMPANY SHARE ANALYSIS 116
16.2.4 PRODUCT PORTFOLIO 116
16.2.5 RECENT DEVELOPMENT 116
16.3 THERMO FISHER SCIENTIFIC INC. 117
16.3.1 COMPANY SNAPSHOT 117
16.3.2 REVENUE ANALYSIS 117
16.3.3 COMPANY SHARE ANALYSIS 118
16.3.4 PRODUCT PORTFOLIO 118
16.3.5 RECENT DEVELOPMENT 118
16.4 KONINLIJKE PHILIPS N.V. 119
16.4.1 COMPANY SNAPSHOT 119
16.4.2 REVENUE ANALYSIS 119
16.4.3 COMPANY SHARE ANALYSIS 120
16.4.4 PRODUCT PORTFOLIO 120
16.4.5 RECENT DEVELOPMENT 120
16.5 BIO-RAD LABORATORIES, INC. 121
16.5.1 COMPANY SNAPSHOT 121
16.5.2 COMPANY SNAPSHOT 121
16.5.3 COMPANY SHARE ANALYSIS 122
16.5.4 PRODUCT PORTFOLIO 122
16.5.5 RECENT DEVELOPMENT 122
16.6 ABBOTT 123
16.6.1 COMPANY SNAPSHOT 123
16.6.2 REVENUE ANALYSIS 123
16.6.3 PRODUCT PORTFOLIO 124
16.6.4 RECENT DEVELOPMENT 124
16.7 AGILENT TECHNOLOGIES, INC. 125
16.7.1 COMPANY SNAPSHOT 125
16.7.2 REVENUE ANALYSIS 125
16.7.3 PRODUCT PORTFOLIO 126
16.7.4 RECENT DEVELOPMENT 126
16.8 AMBU A/S 127
16.8.1 COMPANY SNAPSHOT 127
16.8.2 REVENUE ANALYSIS 127
16.8.3 PRODUCT PORTFOLIO 128
16.8.4 RECENT DEVELOPMENT 128
16.9 BD 129
16.9.1 COMPANY SNAPSHOT 129
16.9.2 REVENUE ANALYSIS 129
16.9.3 PRODUCT PORTFOLIO 130
16.9.4 RECENT DEVELOPMENT 130
16.10 CANON MEDICAL SYSTEMS CORPORATION 131
16.10.1 COMPANY SNAPSHOT 131
16.10.2 REVENUE ANALYSIS 131
16.10.3 PRODUCT PORTFOLIO 132
16.10.4 RECENT DEVELOPMENT 132
16.11 CEPHEID 133
16.11.1 COMPANY SNAPSHOT 133
16.11.2 REVENUE ANALYSIS 133
16.11.3 PRODUCT PORTFOLIO 134
16.11.4 RECENT DEVELOPMENTS 134
16.12 FUJIFILM CORPORATION 135
16.12.1 COMPANY SNAPSHOT 135
16.12.2 REVENUE ANALYSIS 135
16.12.3 PRODUCT PORTFOLIO 136
16.12.4 RECENT DEVELOPMENTS 136
16.13 GENERAL ELECTRIC COMPANY 137
16.13.1 COMPANY SNAPSHOT 137
16.13.2 REVENUE ANALYSIS 137
16.13.3 PRODUCT PORTFOLIO 138
16.13.4 RECENT DEVELOPMENTS 138
16.14 HOLOGIC INC. 139
16.14.1 COMPANY SNAPSHOT 139
16.14.2 REVENUE ANALYSIS 139
16.14.3 PRODUCT PORTFOLIO 140
16.14.4 RECENT DEVELOPMENT 140
16.15 ILLUMINA INC 141
16.15.1 COMPANY SNAPSHOT 141
16.15.2 REVENUE ANALYSIS 141
16.15.3 PRODUCT PORTFOLIO 142
16.15.4 RECENT DEVELOPMENTS 142
16.16 MINFOUND MEDICAL SYSTEMS CO., 143
16.16.1 COMPANY SNAPSHOT 143
16.16.2 PRODUCT PORTFOLIO 143
16.16.3 RECENT DEVELOPMENTS 143
16.17 NEUSOFT CORPORATION 144
16.17.1 COMPANY SNAPSHOT 144
16.17.2 COMPANY SNAPSHOT 144
16.17.3 PRODUCT PORTFOLIO 145
16.17.4 RECENT DEVELOPMENT 145
16.18 QIAGEN 146
16.18.1 COMPANY SNAPSHOT 146
16.18.2 REVENUE ANALYSIS 146
16.18.3 PRODUCT PORTFOLIO 147
16.18.4 RECENT DEVELOPMENT 147
16.19 SIEMENS HEALTHCARE GMBH 148
16.19.1 COMPANY SNAPSHOT 148
16.19.2 REVENUE ANALYSIS 148
16.19.3 PRODUCT PORTFOLIO 149
16.19.4 RECENT DEVELOPMENT 150
16.20 TIME MEDICAL HOLDING. 151
16.20.1 COMPANY SNAPSHOT 151
16.20.2 PRODUCT PORTFOLIO 151
16.20.3 RECENT DEVELOPMENTS 151
17 QUESTIONNAIRE 152
18 RELATED REPORTS 155

Not Sure / Need Reassuring
- Confirm Content
  - Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
    
    Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
    
    Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
    
    Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
- Sample Pages
  - With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
    
    It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
    
    To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Check for Alternatives
  - Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
    
    To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
Prices / Formats / Delivery
- Prices
  - All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
    
    Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Discounts
  - As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
    
    Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
    
    To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Available Currencies
  - Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
    
    Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
    
    To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
- Licenses
  - License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Global Site License
  - The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
    
    It is important to note that this may exclude Parent Companies or Subsidiaries.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Formats
  - The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
    
    If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
- Delivery
  - Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
    
    Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
    
    If a delay in delivery is expected you will be informed about it immediately.
- Shipping Charges
  - As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
    
    If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
Ordering
- By Credit Card
  - We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
    
    Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
    
    For more information on PayU please visit: https://www.payu.pl/en/about-us
- By Money Transfer
  - If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
    
    With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
Security
- Website security
  - We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
    
    Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
- Credit Card Security
  - We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
    
    PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.